WuXi Ap­pTec ac­quires US clin­i­cal re­search firm

BioSpectrum (Asia) - - Company News -

In line with its ex­pan­sion strate­gies, Shang­hai based biotech­nol­ogy and med­i­calde­vice de­vel­oper WuXi Ap­pTec Group has ac­quired US-based clin­i­cal re­search com­pany Re­search Point Global (RPG).

The ac­qui­si­tion will help ex­pand WuXi’s clin­i­cal re­search ca­pa­bil­i­ties in the United States and around the world. The deal will com­bine Re­search Point with WuXi’s ex­ist­ing China-based clin­i­cal de­vel­op­ment ser­vice team.

Upon com­ple­tion of the ac­qui­si­tion, RPG will be­come a wholly owned sub­sidiary of WuXi, with its ser­vice in­te­grated with WuXi’s ex­ist­ing Chin­abased, 500-mem­ber clin­i­cal de­vel­op­ment ser­vice team, or a CRO in the tra­di­tional sense, plus 1,000 clin­i­cal re­search co­or­di­na­tors un­der its site man­age­ment or­ga­ni­za­tion (SMO).

WuXi is in an ac­qui­si­tion spree and has kept up its pace of over­seas in­vest­ments, eye­ing strate­gic ac­qui­si­tions. Ear­lier this year, it formed an al­liance with bio­phar­ma­ceu­ti­cal gi­ant Ab­b­Vie Inc. and life­sciences startup Ge­nomics Medicine Ire­land Ltd. to con­duct pop­u­la­tion ge­nomics re­search.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.